Command Palette

Search for a command to run...

Vitaei Dispatch

The longevity science brief, without the noise.

Every week: one trial update, one expert protocol change, one research digest. Written for people who want to act on the science — not just read about it. Free. No affiliate pitches. No supplement ads.

~2,400 readers · Weekly · Unsubscribe any time

What's inside each issue

Trial updates

Every significant longevity trial result, summarised and contextualised within 48 hours of publication.

Protocol changes

When Sinclair, Attia, Patrick, Huberman, or Johnson update their stacks, we explain what changed and why.

Research digest

One landmark paper per week, distilled to what it means for your biology — no PhD required.

Recent issues

April 2026Trial Update

Urolithin A enters Phase III: what the ATLAS trial means for mitophagy

Amazentis reports 12-month data showing significant improvement in muscle endurance in adults over 65. We break down the mechanism, the dose, and what it means for your protocol.

March 2026Expert Stack

Peter Attia's 2026 protocol changes: what's in, what's out, and why

Attia dropped metformin, doubled his creatine dose, and added ergothioneine. We map each change to the underlying evidence and explain the reasoning.

February 2026Research Digest

The sugar–biological age link: new GlycanAge data from 14,000 participants

A large observational study finds that daily sugar intake above 25g is associated with a 4.2-year increase in biological age as measured by glycan profiling. Interactive chart inside.

January 2026Trial Update

Rapamycin in humans: the PEARL trial 18-month results

The first randomised controlled trial of low-dose rapamycin in healthy adults reports improvements in immune function and no significant adverse effects at 5mg weekly.

Stay current with longevity science.

Join 2,400+ readers who get the weekly digest.